Physician profile
Kyle Seko
NPI 1457715583
$8,916.71
in general payments reported to CMS, 2019-2025
19 companies · $1,186 in 2025
The $1,186 reported for 2025 was more than what 89% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,200 · 2021: $1,463 · 2022: $1,074 · 2023: $756 · 2024: $2,238 · 2025: $1,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,499 · Travel and Lodging: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,499.32 |
| Travel and Lodging | $680.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,124.20 | 2020-2025 | Intracept, Wavewriter Alpha Prime 16, General - Pain Management |
| Trice Medical, INC. | $560.70 | 2022 | |
| Medtronic, INC. | $424.67 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Nevro Corp. | $337.30 | 2021-2022 | |
| Spr Therapeutics, INC | $298.67 | 2021-2024 | Sprint Pns System |
| Merz Pharmaceuticals, LLC | $208.17 | 2021-2025 | Xeomin |
| Abbott Laboratories | $200.93 | 2021-2024 | Eterna |
| Relievant Medsystems, INC. | $132.18 | 2023 | Intracept |
| Averitas Pharma INC. | $84.34 | 2024-2025 | Qutenza |
| Radius Health, INC. | $82.06 | 2023-2024 | Tymlos |
| Stryker Corporation | $57.72 | 2025 | Mild Device Kit |
| Forte Bio-Pharma LLC | $57.06 | 2024 | Prolate, Nalocet |
| Bioventus LLC | $52.27 | 2024-2025 | Durolane, Xcell |
| Pacira Pharmaceuticals Incorporated | $24.93 | 2024 | Iovera |
| Curonix LLC | $22.28 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $19.29 | 2025 | Triluron, Hymovis |
| Depuy Synthes Sales INC. | $16.78 | 2024 | Monovisc, Orthovisc |
| Avanos Medical | $15.83 | 2021 | |
| Globus Medical, INC. | $14.31 | 2025 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Seko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.